Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiac Science Inc. DFIB (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Marc Phelan who wrote (77)	4/11/2002 10:29:39 AM
From: GemSeeker	Read Replies (1) \| Respond to of 174

Lack of market response probably has more to do with the 67 million shares outstanding. About 3 times the norm for comparable young biotech companies.

To: Marc Phelan who wrote (77)	4/11/2002 11:52:27 AM
From: Skywatcher	Respond to of 174

Yeah, everything in this sector and telecoms getting hammered today....thought we might have a decent point for a breakout yesterday on the market.....NOT! Hoping the 2.50 range will hold for sure here.....not ready to watch it head to 2...... CC

To: Marc Phelan who wrote (77)	4/16/2002 10:02:47 PM
From: Skywatcher	Read Replies (1) \| Respond to of 174

Cardiac Science Granted Additional U.S. and European Patents Covering Defibrillator Technologies Company Intellectual Property Portfolio Now Stands at 64 Issued Patents IRVINE, Calif., April 16 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (Nasdaq: DFIB - news) today announced it has been granted two additional U.S. patents and a European patent covering technology embodied in its Powerheart® Automatic External Defibrillator (AED), its Powerheart® CRM(TM) and its wearable defibrillator product, bringing the total of the Company's issued patents to 64 and further strengthening its intellectual property portfolio. The U.S. Patents cover an AED battery status indicator and the remote collection of information from a wearable defibrillator; the European patent extends the protection of the Company's proprietary biphasic energy waveform to Europe. Cardiac Science has filed approximately 10 additional patents, which are pending, related to its technology platform and applications in both hospital and public access defibrillator products. At least the good news keeps comin CC